Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India

被引:8
作者
Vanathi, Murugesan [1 ]
Naik, Ravinder [1 ]
Sidhu, Navneet [1 ]
Ahmed, Nishat Hussain [2 ]
Gupta, Noopur [1 ]
Tandon, Radhika [1 ]
机构
[1] All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Cornea Lens & Refract Surg Serv, New Delhi, India
[2] All India Inst Med Sci, Dr R P Ctr Ophthalm Sci, Ocular Microbiol Serv, New Delhi, India
关键词
Amphotericin B; antifungal susceptibility testing; fungal keratitis; natamycin; posaconazole; IN-VITRO SUSCEPTIBILITY; MOLECULAR CHARACTERIZATION; FUSARIUM KERATITIS; FILAMENTOUS FUNGI; AMPHOTERICIN-B; SOUTH-INDIA; ASPERGILLUS; VORICONAZOLE; RESISTANCE; AGENTS;
D O I
10.4103/ijo.IJO_855_22
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the antifungal susceptibility of common corneal pathogenic fungi to antifungal agents in the North Indian population. Methods: Prospective study of the antifungal sensitivity testing (natamycin, amphotericin B, voriconazole, itraconazole, fluconazole, posaconazole, caspofungin, micafungin) of fungal isolates from 50 cases of culture positive fungal keratitis by using E test method. Details noted included demographic data, visual acuity, clinical details, grade of keratitis, healing time, and success in medical management. Results: Of 50 patients with fungal keratitis (mean age: 40.28 +/- 16.77 years), 12 eyes healed within 3 weeks, 14 had a delayed healing response, and 24 had chronic keratitis. Among the 15 cases of Fusarium isolates, 93.3% were sensitive to natamycin, while 40% to amphotericin B; 66.6% to voriconazole, 13.4% to itraconazole and fluconazole each. 80% of Fusarium cases (n = 12) showed susceptibility to posaconazole. Among Aspergillus flavus isolates, 53.4% (n = 8) were sensitive to natamycin, with only 40% (n = 7) showing sensitivity to amphotericin B and good susceptibility to azoles. MIC against susceptible Fusarium spp. for natamycin was 3-16 mu g/mL, amphotericin B: 1-8 mu g/mL, voriconazole: 0.5-1.5 mu g/mL, itraconazole: 0.5-12 mu g/mL, posaconazole: 0.094-1.5 mu g/mL. MIC against Aspergillus flavus was natamycin: 8-32 mu g/mL, amphotericin B: 0.5-16 mu g/mL, voriconazole: 0.025-4 mu g/mL, itraconazole: 0.125-8 mu g/mL, posaconazole: 0.047-0.25 mu g/mL; against Aspergillus niger isolates, to natamycin was 6 mu g/mL (n=1), amphotericin B 8-12 mu g/mL (n = 3), voriconazole: 0.125-0.19 mu g/mL (n = 3), itraconazole: 0.38-0.75 mu g/mL, posaconazole: 0.064-0.19 mu g/mL and against Aspergillus fumigatus (n = 1), was natamycin4 mu g/mL, amphotericin B - 8 mu g/mL, voriconazole 0.25 mu g/mL, itraconazole 1 mu g/mL, and posaconazole 0.19 mu g/mL. MIC against susceptible Acremonium spp. for natamycin was 1.5-16 mu g/mL, amphotericin B: 0.5-8 mu g/mL, voriconazole: 0.19-3 mu g/mL, itraconazole: 0.125 mu g/mL, posaconazole: 0.125-0.5 mu g/mL and against susceptible Curvularia was natamycin 0.75-4 mu g/mL, amphotericin B 0.5-1 mu g/mL, voriconazole 0.125-0.19 mu g/mL, itraconazole 0.047-0.094 mu g/mL, posaconazole 0.047-0.094 mu g/mL. MIC against Mucor spp.+ Rhizopus spp. (n = 1) was natamycin: 8 mu g/mL, amphotericin B: 0.75 mu g/mL, posaconazole: 1.5 mu g/mL. MIC against of Alternaria (n = 1) was voriconazole: 0.19 mu g/mL, posaconazole: 0.094 mu g/mL. MIC against Penicillium (n=1) was natamycin: 8 mu g/mL, voriconazole: 0.25 mu g/mL, itraconazole: 0.5 mu g/mL, and Posaconazole: 0.125 mu g/mL. Conclusion: Our observations highlight the variations in susceptibility to antifungal agents. Posaconazole seems to be effective with low MIC against common corneal pathogenic fungal isolates.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 56 条
[1]   Successful Salvage Treatment of Scedosporium apiospermum Keratitis with Topical Voriconazole After Failure of Natamycin [J].
Al-Badriyeh, Daoud ;
Leung, Lok ;
Davies, Geoffrey E. ;
Stewart, Kay ;
Kong, David .
ANNALS OF PHARMACOTHERAPY, 2009, 43 (06) :1139-1142
[2]   Echinocandin resistance: an emerging clinical problem? [J].
Arendrup, Maiken C. ;
Perlin, David S. .
CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) :484-492
[3]   Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus [J].
Arikan, Sevtap ;
Sancak, Banu ;
Alp, Sehnaz ;
Hascelik, Gulsen ;
Mcnicholas, Paul .
MEDICAL MYCOLOGY, 2008, 46 (06) :567-573
[4]   Current status of antifungal susceptibility testing methods [J].
Arikan, Sevtap .
MEDICAL MYCOLOGY, 2007, 45 (07) :569-587
[5]  
Bansal Yashik, 2019, Curr Med Mycol, V5, P43, DOI 10.18502/cmm.5.4.2149
[6]   Spectrum of fungal keratitis in North India [J].
Chowdhary, A ;
Singh, K .
CORNEA, 2005, 24 (01) :8-15
[7]   Medical interventions for fungal keratitis [J].
FlorCruz, Nilo Vincent ;
Peczon, Ildefonso V. ;
Evans, Jennifer R. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02)
[8]   Microscopic Evaluation, Molecular Identification, Antifungal Susceptibility, and Clinical Outcomes in Fusarium, Aspergillus and, Dematiaceous Keratitis [J].
Gajjar, Devarshi U. ;
Pal, Anuradha K. ;
Ghodadra, Bharat K. ;
Vasavada, Abhay R. .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[9]   Fungal keratitis in London - Microbiological and clinical evaluation [J].
Galarreta, David J. ;
Tuft, Stephen J. ;
Ramsay, Andrew ;
Dart, John K. G. .
CORNEA, 2007, 26 (09) :1082-1086
[10]   Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance [J].
Ghannoum, MA ;
Rice, LB .
CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (04) :501-+